Patel Brijesh R, Choudhury Maitrayee
Colchester General Hospital, Colchester, UK.
BMJ Case Rep. 2011 Jan 11;2011:bcr1220092552. doi: 10.1136/bcr.12.2009.2552.
As 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ('statins') are being increasingly prescribed for the prevention of cardiovascular disease, this case report describes adverse effects of statin therapy which can sometimes be fatal. It highlights the need for physicians to be aware of individual patient risk factors predisposing to statin induced myopathy. It also highlights the need for further research into cholesterol lowering drugs which do not have such side effects. When prescribing statins for patients, we must also explain potential side effects following initiation of therapy and with dose titrations.
由于3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂（“他汀类药物”）越来越多地被用于预防心血管疾病，本病例报告描述了他汀类药物治疗的不良反应，这些不良反应有时可能是致命的。它强调了医生需要了解易导致他汀类药物引起肌病的个体患者风险因素。它还强调了对没有此类副作用的降胆固醇药物进行进一步研究的必要性。在为患者开他汀类药物时，我们还必须解释治疗开始后以及剂量滴定后的潜在副作用。
